Reneo Pharmaceuticals, Inc.
NASDAQ:RPHM
1.82 (USD) • At close October 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Reneo Pharmaceuticals, Inc. |
Symbool | RPHM |
Munteenheid | USD |
Prijs | 18.2 |
Beurswaarde | 60,840,416 |
Dividendpercentage | 0% |
52-weken bereik | 1.68 - 82.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Gregory J. Flesher |
Website | https://reneopharma.com |
An error occurred while fetching data.
Over Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)